INFORMATION DISCLOSHREE	
STATEMENT BY APPLICANT	\ 83:

Application No. 10/644,277

Filing Date August 19, 2003

First Named Inventor Jean M. Gudas

Art Unit 1643

Examiner Parithosh K. Tungaturthi

(Multiple sheets used when necessary) 1 1 2005

Attorney Docket No. ABGENIX.091A

	U.S. PATENT DOCUMENTS										
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear						
•											

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹			
15,00		WO 02/02640	01/10/2002	Novartis AG					
					·				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
PWI		Patent Abstracts of Japan. Vol. 1999, No.8 (1999). 11 06052, Teijin Ltd.	
		Patent Abstracts of Japan. Vol. 1997, No. 7 (1997). 09 067399, Mitsui Toatsu Chem. Inc.	
		Kaji et al. "Analysis of peptide motifs recognized with anti-MCP-1 monoclonal antibody." Peptide Science. 33-36 (1999).	
		Yoshimura et al. "Production and characterization of mouse monoclonal antibodies against human monocyte chemoattractant protein-1." Journal of Immunology. 147(7):2229-2233 (1991).	
		Zhang et al. "Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1 mediated protein that inhibits MCP-1 mediated monocyte chemotaxis." <i>Journal of Biological Chemistry</i> . 269(22):15918-159924 (2003).	

1976870: 100605/CAP

	/ م		\angle					
Examiner Signature	Ynl	1) (Date Considered	11.	160	
*Evaminas Initial If sa	1050000		oidor	d whother or not citatic	on in in conformance with MRED 600	70	outling through eit	-4 164

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

۲ - °C	kFő	O-1449 U.S. DEPARTMEN PATENT AND TR RMATION DISCLOSURE STATE BY APPLICANT	ADEMARK OF		ATTY. DOCKET NO. ABGENIX.091A	APPLICA 10/644	ATION NO. ,277			
	AKIK OS	ST APPLICANT			APPLICANT Gudas et al.					
PENT & TRAC	ĵijs 	SEVERAL SHEETS IF NECES	SARY)		FILING DATE August 19, 2003	GROUP Not As				
		<u>.</u>		- (J.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING (IF APPR	DATE OPRIAT	
				FO	REIGN PATENT DOCUMENTS					
EXAMINER	Γ	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIAL								YES	NC	
POT	1.	WO 01/89565 A1	11/29/01	PCI						
	_	,	-							
			 							
		•	 							
***	-									
	L						l		1	
EXAMINER INITIAL					(INCLUDING AUTHOR, TITLE, DATE, PERTINE		ETC.)			
POT	2.	PCT International Search	Report, Int	terna	tional Application No. PCT/US03/262	32				
•	L						i			
	-		· · · · · · · · · · · · · · · · · · ·			<u>.</u> .				
-	┞									
•										
					•					
:\DOCS\ET	A/E	TA-2351.DOC\090204\lvo								
							·			
						•	•			

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

DATE CONSIDERED

EXAMINER

FOREIGN PATENT DOCUMENTS									
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIAL							YES	МО	
POT	1.	WO 01/89565	11/29/01						
-									
				·					

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PW	2.	Bradwell et al., "Control of hypercalcaemia of parathyroid carcinoma by immunisation," Lancet, 353: 370-373 (1999)
	3.	Hemmerich et al., "Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2," Biochemistry, 38: 13013-13025 (1999)
	4.	Jarnagin et al., "Identification of Surface Residues of the Monocyte Chemotactic Protein 1 That Affect Signaling through the Receptor CCR2," <i>Biochemistry</i> , 38: 16167-16177 (1999)
	5.	Logue et al., "Production and characterisation of monoclonal antibodies to parathyroid hormone (1-34)," J. Immunol. Methods, 137: 159-166 (1991)
	6.	Magerlein et al., "Production of Sequence Specific Polyclonal Antibodies to Human Parathyroid Hormone 1-37 by Immunization with Multiple Antigenic Peptides," <i>Drug Res.</i> , 48: 783-787 (1998)
	7.	Vieira et al., "Monoclonal Antibodies to Bovine Parathyroid Hormone: Production and Characterization," Braz. J. Med. Biol. Res., 21: 1005-1011 (1988)
[]	8.	Visser et al., "Production and Characterization of Antisera to Synthetic 1-34 Human Parathyroid Hormone Fragments: Possible Implications for the Correctness of Proposed Structures," <i>Acta Endocrinol.</i> , 90: 90-102 (1979)

S:\DOCS\SRG\SRG-1923.DOC\082803\Ivo

EXAMINER	16 6V	V	DATE CONSIDERED 2/2/
*EXAMINER: I	NITIAL IF CITATIO	N CONSI	DERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT
			ED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT